Cytarabine PLGA Loading: Solvent Evaporation & Burst Control
Solvent Evaporation Kinetics: Dichloromethane vs. Ethyl Acetate in Cytarabine-Loaded PLGA Microparticle Formation
When encapsulating cytarabine (Ara-C, 1-beta-D-Arabinofuranosylcytosine) in PLGA microparticles, the choice of organic solvent governs both encapsulation efficiency and burst release. Dichloromethane (DCM) remains the workhorse due to its high volatility and PLGA solubility, but its rapid evaporation often traps the hydrophilic cytarabine near the particle surface, exacerbating initial dose dumping. Ethyl acetate, a less toxic alternative, offers slower evaporation kinetics that can improve drug distribution within the polymer matrix. However, its lower PLGA solubility demands careful temperature control during emulsification to avoid premature polymer precipitation. In our field trials, we observed that a 70:30 DCM:ethyl acetate mixture at 25°C yielded a more uniform cytarabine dispersion, reducing surface-localized drug crystals. This is critical for achieving a pharmaceutical grade drop-in replacement that matches the performance benchmark of existing sustained-release formulations. For R&D managers, the solvent system must be tuned to the specific PLGA copolymer ratio; higher glycolide content accelerates degradation but also increases hydrophilicity, which can alter solvent partitioning. A formulation guide should always include a solvent screening step, as even trace water in the organic phase can induce cytarabine hydrolysis, forming uracil arabinoside—a degradation product that compromises potency.
Interfacial Tension Management via PVA Molecular Weight Selection for Emulsion Stability and Burst Release Control
Poly(vinyl alcohol) (PVA) is the most common stabilizer for the oil-in-water emulsion used in solvent evaporation. The molecular weight and hydrolysis degree of PVA directly influence interfacial tension, which in turn dictates particle size distribution and surface porosity. Low molecular weight PVA (13–23 kDa) reduces interfacial tension more effectively, yielding smaller particles (<10 µm) but often with higher burst release due to increased surface area. High molecular weight PVA (30–70 kDa) forms a thicker protective layer, but residual PVA on the particle surface can hinder cytarabine release and may require additional washing steps. A non-standard parameter we've encountered is the viscosity shift of the aqueous phase when using high-concentration PVA solutions at sub-ambient temperatures (4°C). This can lead to inconsistent droplet breakup during homogenization, resulting in a bimodal particle size distribution. To mitigate this, we recommend pre-equilibrating the PVA solution to 20°C before emulsification. For a drop-in replacement product, the PVA grade must be specified in the COA, as it affects both the initial burst and the long-term release profile. Our bulk cytarabine-loaded PLGA microparticles are manufactured using a carefully selected PVA grade that ensures batch-to-batch consistency, aligning with GMP standards.
Mitigating Surface Adsorption and Initial Dose Dumping of Cytarabine in PLGA Microparticles
Burst release—the rapid elution of drug within the first 24 hours—is a persistent challenge with hydrophilic small molecules like cytarabine. This often stems from drug adsorbed on the particle surface or entrapped in the superficial polymer layers. Strategies to mitigate this include: (1) increasing the PLGA concentration in the organic phase to raise viscosity and slow drug diffusion to the interface; (2) incorporating a co-solvent like acetone to accelerate polymer precipitation and trap drug deeper; and (3) post-fabrication annealing at temperatures just above the glass transition temperature (Tg) of PLGA to heal surface defects. In our experience, a brief annealing step at 45°C for 2 hours reduced the 24-hour burst from 35% to 12% for a 50:50 PLGA formulation. However, care must be taken to avoid thermal degradation of cytarabine; we monitor for the appearance of a yellow discoloration, which indicates decomposition. For those seeking a reliable equivalent to commercial sustained-release cytarabine formulations, our product undergoes rigorous burst release testing per batch-specific COA. Additionally, we have observed that trace impurities in the PLGA raw material, such as residual monomers, can plasticize the polymer and increase burst release. Therefore, sourcing high-purity PLGA is non-negotiable.
Drying Protocols to Preserve PLGA Polymer Integrity and Cytarabine Stability in Bulk Microparticle Production
The final drying step is critical for both polymer integrity and drug stability. Freeze-drying (lyophilization) is commonly used, but the formation of ice crystals can shear the PLGA matrix, creating microcracks that lead to burst release. We have found that adding a cryoprotectant like trehalose (5% w/v) to the aqueous suspension before freezing preserves particle morphology. Alternatively, vacuum drying at 30°C is gentler but requires longer cycles. A key non-standard parameter is the residual moisture content: PLGA is hygroscopic, and moisture above 1% can accelerate hydrolysis during storage, reducing molecular weight and altering release kinetics. We specify a residual moisture limit of <0.5% in our COA. For bulk packaging, we use double-layer aluminum foil bags with desiccant inside 210L drums to maintain this specification. When scaling up, the drying endpoint must be validated by Karl Fischer titration, not just weight loss, to ensure batch uniformity. Our GMP-compliant drying protocols are designed to deliver a product that performs as a seamless drop-in replacement, with identical technical parameters to the original formulation.
Bulk Packaging and COA Parameters for Cytarabine-Loaded PLGA Microparticles: IBC and 210L Drum Specifications
For industrial-scale procurement, packaging integrity is paramount. Our cytarabine-loaded PLGA microparticles are supplied in two standard formats: 210L steel drums with polyethylene liners for quantities up to 50 kg, and intermediate bulk containers (IBCs) for larger orders. Each drum is nitrogen-flushed to displace oxygen and moisture, and sealed with a tamper-evident ring. The COA includes critical parameters: cytarabine content (HPLC, typically 10–20% w/w), particle size (D50, laser diffraction), residual PVA, residual solvents (DCM, ethyl acetate), and in vitro release profile (PBS, pH 7.4, 37°C). We also report the glass transition temperature (DSC) and molecular weight (GPC) of the PLGA matrix. For logistics, we recommend storage at 2–8°C to minimize polymer degradation; however, short-term excursions up to 25°C are acceptable if the product is used within 3 months. Our regulatory support team can provide a drug master file (DMF) letter of authorization upon request. As a global manufacturer, we ensure that every batch meets the stringent requirements for pharmaceutical grade applications, making it a true equivalent to in-house developed formulations.
| Parameter | Specification | Method |
|---|---|---|
| Cytarabine Content | 15.0 ± 1.5% w/w | HPLC-UV |
| Particle Size (D50) | 20–40 µm | Laser Diffraction |
| Residual PVA | ≤ 0.5% w/w | Colorimetric |
| Residual DCM | ≤ 600 ppm | GC-HS |
| Residual Ethyl Acetate | ≤ 5000 ppm | GC-HS |
| Burst Release (24h) | ≤ 15% | In Vitro Dissolution |
| Moisture Content | ≤ 0.5% | Karl Fischer |
| PLGA Molecular Weight | 40–60 kDa | GPC |
Frequently Asked Questions
How does PVA concentration influence particle size distribution in cytarabine-loaded PLGA microparticles?
PVA concentration in the external aqueous phase directly affects interfacial tension and continuous phase viscosity. At low concentrations (0.5% w/v), interfacial tension is higher, leading to larger droplets and broader size distribution. Increasing PVA to 2% w/v reduces interfacial tension and stabilizes smaller droplets, yielding a narrower size distribution with a D50 around 20 µm. However, excessive PVA (>3% w/v) can increase viscosity, causing uneven shear during homogenization and a bimodal distribution. For cytarabine, we have found that 1.5% PVA (13–23 kDa, 87–89% hydrolyzed) provides the best balance for a 50:50 PLGA formulation.
What drying temperature thresholds prevent polymer chain scission or active ingredient degradation?
For PLGA, the glass transition temperature (Tg) is typically 40–50°C depending on the copolymer ratio. Drying above Tg can cause particle aggregation and chain mobility that leads to hydrolysis. We recommend vacuum drying at ≤30°C to stay well below Tg. For cytarabine, thermal degradation accelerates above 60°C, but even at 40°C, prolonged exposure can cause deamination to uracil arabinoside. Therefore, a drying temperature of 25–30°C with a vacuum of <10 mbar is optimal. Lyophilization with a primary drying temperature of -20°C and secondary drying at 20°C is also effective, provided a cryoprotectant is used.
Can cytarabine-loaded PLGA microparticles be terminally sterilized?
Terminal sterilization by gamma irradiation or ethylene oxide is not recommended, as both can degrade PLGA and cytarabine. Gamma irradiation causes chain scission, reducing molecular weight and accelerating release. Ethylene oxide leaves toxic residues. Aseptic processing is the preferred method. Our manufacturing process includes sterile filtration of the PVA solution and all processing under ISO 5 conditions. The final product is tested for bioburden and endotoxins per GMP standards.
What is the shelf life of cytarabine-loaded PLGA microparticles?
When stored at 2–8°C in sealed, nitrogen-flushed containers, the shelf life is 24 months from the date of manufacture. Real-time stability data show less than 5% loss of cytarabine content and no significant change in release profile over this period. Accelerated stability studies at 25°C/60% RH indicate a shelf life of 6 months under these conditions. Each batch is shipped with a stability-indicating COA.
Sourcing and Technical Support
As a leading global manufacturer of pharmaceutical intermediates, NINGBO INNO PHARMCHEM CO.,LTD. offers cytarabine-loaded PLGA microparticles that serve as a direct drop-in replacement for your sustained-release formulation needs. Our product is manufactured under GMP standards, with full regulatory support including DMF access. For those working on ophthalmic applications, our article on formulating cytarabine ophthalmic drops with preservative compatibility and light stability provides additional guidance. If your project involves hydrogel-based delivery, see our insights on cytarabine dispersion in carbomer hydrogels for viscosity control and syringeability. For bulk pricing and to request a sample COA, visit our product page: high-purity cytarabine API for pharmaceutical manufacturing. Partner with a verified manufacturer. Connect with our procurement specialists to lock in your supply agreements.